A concise review on the therapeutics of obesity.

Article Details

Citation

Bray GA

A concise review on the therapeutics of obesity.

Nutrition. 2000 Oct;16(10):953-60.

PubMed ID
11054601 [ View in PubMed
]
Abstract

Drugs to treat obesity can be divided into three groups: those that reduce food intake; those that alter metabolism; and those that increase thermogenesis. Monoamines acting on noradrenergic receptors, serotonin receptors, dopamine receptors, and histamine receptors can reduce food intake. A number of peptides also affect food intake. The noradrenergic drugs phentermine, diethylpropion, mazindol, benzphetamine, and phendimetrazine are approved only for short-term use. Sibutramine, a norepinephrine-serotonin reuptake inhibitor, is approved for long-term use. Orlistat inhibits pancreatic lipase and can block 30% of the triacylglycerol hydrolysis in subjects eating a 30% fat diet. The only thermogenic drug combination that has been tested is ephedrine and caffeine, but this treatment has not been approved by regulatory agencies. In clinical trials other drugs that may modulate peptide-feeding systems are being developed.

DrugBank Data that Cites this Article

Drugs
Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
OrlistatPancreatic triacylglycerol lipaseProteinHumans
Yes
Inhibitor
Details
PhendimetrazineAlpha-1A adrenergic receptorProteinHumans
Yes
Agonist
Details
PhendimetrazineAlpha-1B adrenergic receptorProteinHumans
Unknown
Agonist
Details